Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5N0Y

hPAD4 crystal complex with AFM-30a

Summary for 5N0Y
Entry DOI10.2210/pdb5n0y/pdb
Related5N0M
DescriptorProtein-arginine deiminase type-4, SULFATE ION, CALCIUM ION, ... (5 entities in total)
Functional Keywordshydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
Biological sourceHomo sapiens (Human)
Cellular locationCytoplasm: Q9UM07
Total number of polymer chains1
Total formula weight75676.77
Authors
Beaumont, E.,Kerry, P.,Thompson, P.,Muth, A.,Subramanian, V.,Nagar, M.,Srinath, H.,Clancy, K.,Parelkar, S. (deposition date: 2017-02-03, release date: 2017-05-24, Last modification date: 2024-11-20)
Primary citationMuth, A.,Subramanian, V.,Beaumont, E.,Nagar, M.,Kerry, P.,McEwan, P.,Srinath, H.,Clancy, K.,Parelkar, S.,Thompson, P.R.
Development of a Selective Inhibitor of Protein Arginine Deiminase 2.
J. Med. Chem., 60:3198-3211, 2017
Cited by
PubMed Abstract: Protein arginine deiminase 2 (PAD2) plays a key role in the onset and progression of multiple sclerosis, rheumatoid arthritis, and breast cancer. To date, no PAD2-selective inhibitor has been developed. Such a compound will be critical for elucidating the biological roles of this isozyme and may ultimately be useful for treating specific diseases in which PAD2 activity is dysregulated. To achieve this goal, we synthesized a series of benzimidazole-based derivatives of Cl-amidine, hypothesizing that this scaffold would allow access to a series of PAD2-selective inhibitors with enhanced cellular efficacy. Herein, we demonstrate that substitutions at both the N-terminus and C-terminus of Cl-amidine result in >100-fold increases in PAD2 potency and selectivity (30a, 41a, and 49a) as well as cellular efficacy (30a). Notably, these compounds use the far less reactive fluoroacetamidine warhead. In total, we predict that 30a will be a critical tool for understanding cellular PAD2 function and sets the stage for treating diseases in which PAD2 activity is dysregulated.
PubMed: 28328217
DOI: 10.1021/acs.jmedchem.7b00274
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.23 Å)
Structure validation

229183

PDB entries from 2024-12-18

PDB statisticsPDBj update infoContact PDBjnumon